Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

In 2022, Biogen's CEO was replaced by Christopher Wiebacher, who previously headed Sanofi. Since then, a new development strategy has been adopted within Biogen, and the company has actively begun ...

Since Biogen has shed US$697m from its value in the ... BIIB Earnings Per Share Growth April 1st 2025 We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly ...